The Director of the National Medical Products Administration Huang Guo conducted an inspection and supervision at a vaccine production company.

On June 24, Huang Gou, Secretary of the Party Group and Director of the National Medical Products Administration, led a team to visit Sinovac Biotech, a vaccine technology company in Dalian, Liaoning Province, to supervise the inspection of vaccines. Huang emphasized the need to tighten supervision responsibility and enterprise main responsibility, strictly comparing the list of responsibilities, and resolutely establishing the baseline for vaccine quality and safety. It is necessary to strictly implement the vaccine inspection system, continuously conduct routine inspections of vaccine production companies, implement on-site supervision systems, and address risks at the source. It is important to continuously improve the technical support system for vaccine regulation, enhance the level of batch approval, on-site inspections, drug vigilance, and other work, and safeguard the high-quality development of vaccines with strong technical capabilities.